Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
Type:
Application
Filed:
April 13, 2010
Publication date:
September 30, 2010
Applicant:
EPOPLUS GMBH & CO. KG
Inventors:
Ferdinand Hermann Bahlmann, Hermann Haller
Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
Type:
Application
Filed:
April 13, 2010
Publication date:
September 30, 2010
Applicant:
EPOPLUS GMBH & CO. KG
Inventors:
Ferdinand Hermann Bahlmann, Hermann Haller
Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
Type:
Application
Filed:
April 13, 2010
Publication date:
September 30, 2010
Applicant:
EPOPLUS GMBH & CO. KG
Inventors:
Ferdinand Hermann Bahlmann, Hermann Haller
Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
Type:
Grant
Filed:
July 25, 2003
Date of Patent:
June 29, 2010
Assignee:
Epoplus GmbH & Co. KG
Inventors:
Ferdinand Hermann Bahlmann, Hermann Haller